Last reviewed · How we verify
Docetaxel, Capecitabine, Cisplatin, Bevacizumab
Docetaxel, Capecitabine, Cisplatin, Bevacizumab is a Taxane, Thymidylate synthase inhibitor, Platinum-based alkylating agent, Monoclonal antibody Small molecule drug developed by Asan Medical Center. It is currently in Phase 2 development for Metastatic breast cancer, Metastatic non-small cell lung cancer, Metastatic gastric cancer, Metastatic colorectal cancer.
Docetaxel is a microtubule inhibitor that disrupts cell division, Capecitabine is a thymidylate synthase inhibitor that interferes with DNA synthesis, Cisplatin is a platinum-based alkylating agent that cross-links DNA, Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor.
Docetaxel is a microtubule inhibitor that disrupts cell division, Capecitabine is a thymidylate synthase inhibitor that interferes with DNA synthesis, Cisplatin is a platinum-based alkylating agent that cross-links DNA, Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor. Used for Metastatic breast cancer, Metastatic non-small cell lung cancer, Metastatic gastric cancer, Metastatic colorectal cancer.
At a glance
| Generic name | Docetaxel, Capecitabine, Cisplatin, Bevacizumab |
|---|---|
| Sponsor | Asan Medical Center |
| Drug class | Taxane, Thymidylate synthase inhibitor, Platinum-based alkylating agent, Monoclonal antibody |
| Target | Microtubules, Thymidylate synthase, DNA, Vascular endothelial growth factor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Docetaxel works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division. Capecitabine is converted into 5-fluorouracil, which inhibits thymidylate synthase and interferes with DNA synthesis. Cisplatin forms platinum-DNA adducts that prevent DNA replication and transcription. Bevacizumab binds to vascular endothelial growth factor and prevents its interaction with its receptor, thereby inhibiting angiogenesis.
Approved indications
- Metastatic breast cancer, Metastatic non-small cell lung cancer, Metastatic gastric cancer, Metastatic colorectal cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Fatigue
- Nausea
- Diarrhea
- Vomiting
- Headache
- Dizziness
- Rash
Key clinical trials
- MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) (PHASE2)
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (PHASE2)
- Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer (PHASE2)
- Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma (PHASE2)
- Phase I/II Study of Weekly Docetaxel and Cisplatin Together With Capecitabine and Bevacizumab in Advanced Gastric Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Docetaxel, Capecitabine, Cisplatin, Bevacizumab CI brief — competitive landscape report
- Docetaxel, Capecitabine, Cisplatin, Bevacizumab updates RSS · CI watch RSS
- Asan Medical Center portfolio CI
Frequently asked questions about Docetaxel, Capecitabine, Cisplatin, Bevacizumab
What is Docetaxel, Capecitabine, Cisplatin, Bevacizumab?
How does Docetaxel, Capecitabine, Cisplatin, Bevacizumab work?
What is Docetaxel, Capecitabine, Cisplatin, Bevacizumab used for?
Who makes Docetaxel, Capecitabine, Cisplatin, Bevacizumab?
What drug class is Docetaxel, Capecitabine, Cisplatin, Bevacizumab in?
What development phase is Docetaxel, Capecitabine, Cisplatin, Bevacizumab in?
What are the side effects of Docetaxel, Capecitabine, Cisplatin, Bevacizumab?
What does Docetaxel, Capecitabine, Cisplatin, Bevacizumab target?
Related
- Drug class: All Taxane, Thymidylate synthase inhibitor, Platinum-based alkylating agent, Monoclonal antibody drugs
- Target: All drugs targeting Microtubules, Thymidylate synthase, DNA, Vascular endothelial growth factor
- Manufacturer: Asan Medical Center — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic breast cancer, Metastatic non-small cell lung cancer, Metastatic gastric cancer, Metastatic colorectal cancer